Atripla

Type: Product
Name: Atripla
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Company Update: Gilead Sciences Inc (NASDAQ:GILD) – Europe backs new leukaemia drugs from J&J and Gilead

[Reuters] – Two new leukaemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. The European Medicines Agency said on Friday its experts ... [Published Jutia Group - Jul 25 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Efavirenz use not linked to neurocognitive impairment

People who useantiretroviral regimens containing efavirenz ( Sustiva or Stocrin , alsoin the Atripla coformulation) werenot at higher risk for impaired neurocognitive function, either overall or whenlooking at specific functional domains, researchers ... [Published Aidsmap - Jul 25 2014]
Entities: Efavirenz, HIV/AIDS, Drugs, Risk
First reported Jul 24 2014 - Updated Jul 24 2014 - 4 reports

Gilead beats forecasts as Sovaldi sales soar

US anti-virals specialist biotech firm Gilead Sciences (Nasdaq: GILD) has reported surging second-quarter 2014 sales and profits, boosted by a sharp quarter on quarter rise in revenues from its latest hepatitis C drug Sovaldi (sofosbuvir) and exceed analysts’ ... [Published Pharma Letter - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 24 2014 - 1 reports

Puma Biotechnology: Another Jackpot For Investors

Investors who purchased shares in Puma Biotechnology Inc. before the closing of Wall Street on Tuesday—at around $60 or better at the 52-week low of $33.70 — hit the jackpot.The stock was trading north of $230 on Wednesday, an overnight gain of  293% ... [Published Forbes.com - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Biogen, Gilead Earnings Crush Q2 Estimates

Big-cap biotech leaders Biogen Idec (BIIB) and Gilead Sciences (GILD) easily beat second-quarter earnings estimates and received product approvals Wednesday, but their stocks reacted very differently.Biogenearnings rose 52% vs. a year earlier to $3.49 ... [Published Yahoo! Finance - Jul 23 2014]
First reported Jul 22 2014 - Updated Jul 23 2014 - 1 reports

3 Things You Need to Watch on Gilead Sciences Inc. Earnings Call

1. How sustainable are hepatitis C sales?This is literally the multi-billion dollar question. Sovaldi sales north of $3 billion would be nice. If it can hit $3.5 billion, investors will do a little dance for sure.But while the higher the sales the better, ... [Published Motley Fool - Jul 22 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

A Global Product and Pipeline Analysis of Antiretroviral Drug Development for the Treatment of HIV/AIDS

Key FindingsHuman Immunodeficiency Virus (HIV) AntiretroviralsThe 2006 launch of Atripla, the first single-tablet regimen (STR) for the treatment of HIV infection, marked an important advancement in antiretroviral therapy (ART), significantly enhancing ... [Published MarketResearch.com - Jul 16 2014]
First reported Jul 13 2014 - Updated Jul 13 2014 - 1 reports

Obamacare's Surprising HIV Drug Demand

The Affordable Care Act has established basic core health requirements for insurance plans offered in the U.S. that support those diagnosed with life-threatening chronic diseases, including HIV.As a result, Express Scripts has reported that demand for ... [Published Motley Fool Discussion Boards - Jul 13 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

Bone problems and hepatitis C

A new analysis shows that people whohave both HIV and hepatitis C have an increased risk of having osteoporosis(weak bones). When a person has osteoporosis, their bones are more brittleand fragile than usual – so fragile that a fall can cause them to ... [Published Aidsmap - Jul 10 2014]
First reported Jul 03 2014 - Updated Jul 04 2014 - 1 reports

Bristol-Myers recalls 6 lots of injected Coumadin

Particulate found in samples of the IV form, which BMS stopped making in AprilShareToolsBristol-Myers Squibb ($BMY) in April quit making injected Coumadin, the form used in the rare cases when patients can't take the oral formulation. But there is still ... [Published FiercePharmaManufacturing - Jul 03 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 1 reports

12 Years Later

I took the call on a Thursday evening, and browbeat the nurse into telling me which test was abnormal. HIV was the furthest answer from my mind, but there it was. "You'll be dead in a week," I thought to myself. My wife came home, I told her and within ... [Published The Body - Jun 23 2014]
Entities: HIV/AIDS, Workers, Atripla
First reported May 12 2014 - Updated May 12 2014 - 1 reports

Human medicines European public assessment report (EPAR): Atripla, efavirenz / emtricitabine / tenofovir disoproxil, Revision: 15, Authorised

Quotes

researchers concluded. "Even though confounding by indication may play a"
"GILD reported a 2Q that soundly beat SELL side consensus, but was roughly in line with what I perceive to be buy side expectations" wrote ISI Group analyst Mark Schoenebaum in an email to clients. He added that the new revenue guidance agrees with analysts' estimates
...respective organizations exemplify the range and depth of CHI's membership and all we stand for," said CHI President and CEO Todd Gillenwater. "The experience and expertise James, Shlomo and Jim bring to bear will further bolster CHI's work to shape and drive state and federal policies that advance biomedical research, investment and innovation in California."

More Content

All (29) | News (25) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Efavirenz use not linked to neurocognitive impa... [Published Aidsmap - Jul 25 2014]
Company Update: Gilead Sciences Inc (NASDAQ:GIL... [Published Jutia Group - Jul 25 2014]
Gilead beats forecasts as Sovaldi sales soar [Published Pharma Letter - Jul 24 2014]
Gilead Crushes Q2 Earnings Estimates as Sovaldi... [Published Yahoo! Finance - Jul 24 2014]
Gilead's Sovaldi soars with sales of $3.48 billion [Published Pharma Times - Jul 24 2014]
Gilead Sciences' (GILD) CEO John Martin on Q2 2... [Published Yahoo! Finance - Jul 24 2014]
Biogen, Gilead Earnings Crush Q2 Estimates [Published Yahoo! Finance - Jul 23 2014]
Puma Biotechnology: Another Jackpot For Investors [Published Forbes.com - Jul 23 2014]
3 Things You Need to Watch on Gilead Sciences I... [Published Motley Fool - Jul 22 2014]
Sofosbuvir + ribavirin cures hepatitis C for mo... [Published Aidsmap - Jul 21 2014]
California Healthcare Institute Adds Executives... [Published Digital Journal - Jul 21 2014]
A Global Product and Pipeline Analysis of Antir... [Published MarketResearch.com - Jul 16 2014]
1 Hidden Blockbuster Lurking in Merck's Pipeline? [Published Motley Fool - Jul 14 2014]
Obamacare's Surprising HIV Drug Demand [Published Motley Fool Discussion Boards - Jul 13 2014]
ACHAP future uncertain as Merck Foundation dono... [Published Sunday Standard Botswana - Jul 10 2014]
Bone problems and hepatitis C [Published Aidsmap - Jul 10 2014]
The 4 Most Important S&P 500 Stocks of the Past... [Published Motley Fool Discussion Boards - Jul 05 2014]
Bristol-Myers recalls 6 lots of injected Coumadin [Published FiercePharmaManufacturing - Jul 03 2014]
Why Gilead Sciences Is a Must-Own Stock [Published Wall St. Cheat Sheet - Jun 30 2014]
BRISTOL MYERS SQUIBB : Patent Issued for Betuli... [Published 4 Traders - Jun 26 2014]
4 Convincing Reasons Why Gilead Sciences Should... [Published Seeking Alpha - Jun 25 2014]
12 Years Later [Published The Body - Jun 23 2014]
9 Years Between Diagnosis and My First HIV Pill [Published The Body - Jun 20 2014]
Janssen and ViiV to Develop NRTI-free Single-ta... [Published HIV and Hepatitis.com - Jun 19 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 12 2014]
Biotech Stock Mailbag: Amarin, Cytrx, Sangamo a... [Published The Street Latest - Mar 21 2014]
Gilead Sciences: What Happened Today? [Published BARRONS.com Stocks To Watch Today - Mar 07 2014]
Anyone Could Spare Me On Atripla? [Published HealthBoards - Feb 03 2014]
US FDA submission for Tivicay combination [Published TrustNet - Oct 22 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Why Gilead Sciences Is a Must-Own Stock [Published Wall St. Cheat Sheet - Jun 30 2014]
Source: Thinkstock Gilead Sciences Inc . ( NASDAQ:GILD ) is one of my top choices for any stocks moving forward through 2014 into 2015. This company is a behemoth of a biopharmaceutical company. It designs, discovers, develops, and commercializes ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 12 2014]
Gilead Sciences: What Happened Today? [Published BARRONS.com Stocks To Watch Today - Mar 07 2014]
Shares of Gilead Sciences (GILD) fell 3.6% today, and the experts I spoke with said that they didn’t see a catalyst for the drop, one that dragged the entire biotech sector down with it. Now there are two possibilities. StreetInsider.com and the Fly On ...
Anyone Could Spare Me On Atripla? [Published HealthBoards - Feb 03 2014]
Hi, I was wondering if anyone could spare maybe 2 or 3 Atripla tablets? (I live in Baton Rouge). I requested a Refill from my pharmacy and was told that they were unable to refill my prescription because it's showing that I am no longer covered. I filled ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.